

Weekly New Drug Approvals

1 Jul. 2024

1. Batifiban


NMPA Approval Date: Jun. 25th, 2024

Indication: Acute Coronary Syndrome

Mechanism: GP IIb/IIIa antagonists

Dosage form: Injection

Company: Bio-Thera Solutions



Batifiban, a cyclic peptide, is a platelet glycoprotein IIb/IIIa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin $\alpha\beta_3$, Batifiban can be used for research of acute coronary syndromes.



2. Enlonstobart

NMPA Approval Date: Jun. 25th, 2024

Indication: Uterine Cervical Cancer

Mechanism: PD-1 inhibitors

Dosage form: Injection

Company: CSPC Pharmaceutical

Enlonstobart is a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody. This medication activates anti-tumor immune responses by blocking the PD-1 pathway. Early and critical phase 2 studies have shown good therapeutic effects.

3. Ensifentrine

FDA Approval Date: Jun. 26th, 2024


Brand name: Ohtuvayre

Indication: Pulmonary Disease, Chronic Obstructive

Mechanism: PDE3 inhibitors/PDE4 inhibitors

Dosage form: Nebulizer suspension

Company: Verona Pharma



Ensifentrine is the first inhaled treatment for respiratory diseases in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) resulting in bronchodilator and non-steroidal anti-inflammatory effects.